Navigation Links
Monogram Announces a 6-to-1 Reverse Stock Split
Date:10/27/2008

SOUTH SAN FRANCISCO, Calif., Oct. 27 /PRNewswire-FirstCall/ -- Monogram Biosciences, Inc., (Nasdaq: MGRM) today announced that its Board of Directors has approved a 6-to-1 reverse split of its common stock, as previously authorized and approved by the Company's stockholders at the September 19, 2007 annual meeting. The Company's common stock will begin trading on a post- split basis on November 4, 2008, under the temporary trading symbol "MGRMD" for approximately 20 trading days before reverting to "MGRM" on or about December 2, 2008.

As a result of the reverse stock split, every six shares of Monogram Biosciences common stock will be combined into one share of common stock. The reverse stock split affects all the Company's common stock outstanding immediately prior to the effective time of the reverse stock split as well as the number of shares of common stock available for issuance under the Company's equity incentive plans. In addition, the reverse stock split will effect a reduction in the number of shares of common stock issuable upon the conversion of outstanding convertible debt or upon the exercise of stock options or warrants. The Company will pay cash in lieu of fractional shares based on the average of the high and low trading prices of the common stock for the five trading days immediately preceding the effective date of the reverse stock split. The reverse stock split will reduce the number of shares of the Company's common stock outstanding from approximately 135 million to approximately 22.5 million. In addition, the number of authorized shares of common stock will be reduced from 200 million to 84 million shares.

About Monogram

Monogram is advancing individualized medicine by discovering, developing and marketing innovative products to guide and improve treatment of serious infectious diseases and cancer. The Company's products are designed to help doctors optimize treatment regimens for their patients that lead to better outcomes and reduced costs. The Company's technology is also being used by numerous biopharmaceutical companies to develop new and improved anti-viral therapeutics and vaccines as well as targeted cancer therapeutics. More information about the Company and its technology can be found on its web site at http://www.monogrambio.com.

Forward Looking Statements

Certain statements in this press release are forward-looking, including statements regarding the planned reverse split of our common stock. These forward-looking statements are subject to risks and uncertainties and other factors, including potential Nasdaq proceedings to delist our common stock, our ability to regain compliance with Nasdaq listing requirements, the and impact of the reverse split of the shares of our common stock, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

Contacts: Alfred G. Merriweather Jeremiah Hall

Chief Financial Officer Feinstein Kean Healthcare

Tel: 650 624-4576 Tel: 415 677-2700

amerriweather@monogrambio.com jeremiah.hall@fkhealth.com


'/>"/>
SOURCE Monogram Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Monogram Announces Conference Call
2. Monogram Receives NASDAQ Notification
3. Monogram and Dana-Farber Cancer Institute Initiate Evaluation of HERmark(TM) Breast Cancer Assay in Metastatic Breast Cancer
4. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
5. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
6. Monogram Biosciences Announces Second Quarter 2008 Financial Results Conference Call
7. Monogram Biosciences to Present at the Collins Stewart Fourth Annual Growth Conference
8. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
9. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
10. Monogram Announces HERmark(TM) Oral Presentation at the 44th ASCO Annual Meeting
11. Monogram Biosciences Announces First Quarter 2008 Financial Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016   Ginkgo Bioworks , a leading ... was today awarded as one of the World ... world,s most innovative companies. Ginkgo Bioworks is engineering ... real world in the nutrition, health and consumer ... with customers including Fortune 500 companies to design ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of ... higher end machines that use the more unconventional z-dimension of 20mm. Z-dimension ... of the cuvette holder. , FireflySci has developed several Agilent flow cell product ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
Breaking Biology Technology:
(Date:4/13/2016)... 2016  IMPOWER physicians supporting Medicaid patients in ... clinical standard in telehealth thanks to a new partnership ... platform, IMPOWER patients can routinely track key health measurements, ... index, and, when they opt in, share them with ... a local retail location at no cost. By leveraging ...
(Date:3/29/2016)... 2016 LegacyXChange, Inc. (OTC: ... SelectaDNA/CSI Protect are pleased to announce our successful effort ... variety of writing instruments, ensuring athletes signatures against counterfeiting ... from athletes on LegacyXChange will be assured of ongoing ... Bill Bollander , CEO states, "By ...
(Date:3/22/2016)... PROVO and SANDY, Utah ... Ontario (NSO), which operates the highest sample volume laboratory ... and Tute Genomics and UNIConnect, leaders in clinical sequencing ... announced the launch of a project to establish the ... panel. NSO has been contracted by ...
Breaking Biology News(10 mins):